<DOC>
	<DOC>NCT01583244</DOC>
	<brief_summary>The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Orencia® so that the regulatory authority can manage the marketing approval properly.</brief_summary>
	<brief_title>Korean Post-marketing Surveillance for Orencia®</brief_title>
	<detailed_description>Time Perspective: Prospective / Retrospective(On-treatment)</detailed_description>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Patients must be diagnosed with: Adult Rheumatoid arthritis (RA): adult patients with moderatetosevere active RA Or Juvenile idiopathic RA: juvenile patients aged 6 years and older with moderatetosevere active RA Children aged &lt;6 years Pregnant or lactating women Patients who are participating in another study Patients known to be hypersensitive to the active component of the surveillance drug or any other component of the surveillance drug Patients who had a positive tuberculosis screening test but were not treated with standard therapy before participating in the study Patients who have a positive hepatitis virus test Patients who were given a live vaccine concurrently with the surveillance drug or are expected to be given a live vaccine again within 3 months after discontinuation of the surveillance drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>